Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNYTE-ESO: Genetically engineered NY-ESO-1-specific T cells in synovial sarcoma and myxoid/round cell liposarcoma
2024-513032-14-00Phase 2Completed
- Sponsor
- US WorldMeds
- Start
- Jun 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of letetresgene autoleucel in synovial sarcoma (SS) and Myxoid/round cell liposarcoma (MRCLS), sponsored by US WorldMeds. Primary endpoint: Overall Response Rate. Started Jun 2024; status: completed.
02
Drugs
letetresgene autoleucel
03
Conditions
synovial sarcoma (SS)Myxoid/round cell liposarcoma (MRCLS)
Beyond the preview
Go deeper on 2024-513032-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513032-14-00.